Document is current
Any future updates will be listed below
-
Authors
Ross, Samuel E. https://orcid.org/0000-0002-0588-1703
Holliday, Holly https://orcid.org/0000-0002-3022-0114
Wang, Eyden
Zeraati, Mahdi
Tsoli, Maria
Ziegler, David S. https://orcid.org/0000-0001-7451-7916
Dinger, Marcel E. https://orcid.org/0000-0003-4423-934X
-
Funding
Funding for this research was provided by:
Cancer Institute NSW (2025/ECF2608)
Cancer Institute NSW (2022/ECF1425)
Cancer Institute NSW (2022/ECF1421)
Cancer Institute NSW (Program Grant #TPG2037)
Department of Health | National Health and Medical Research Council (Synergy Grant #2019056)
Department of Health | National Health and Medical Research Council (Leadership Grant #APP2017898)
- License Information
-
More Information
Article History
Received: 2 January 2025
Revised: 25 February 2026
Accepted: 11 March 2026
First Online: 26 March 2026
Competing interests
: DSZ reports consulting/advisory board fees from Novartis, Norgine and Medison Pharma and research support from Accendatech.
: This study used established, fully de-identified cell lines and did not involve human participants or identifiable human tissue samples. The SU-DIPG and HSJD-DIPG cell lines were obtained from M. Monje and A. M. Carcaboso, respectively. HSJD-DIPG cells were provided by Hospital Sant Joan de Déu Barcelona under a Material Transfer Agreement (MTA). Isogenic H3K27M-knockout SUDIPGXIII models were obtained from N. Jabado and B. Krug. P000302 cells were developed from the ZERO Childhood Cancer Clinical Trial. All experiments in human primary brain tumor cultures were performed in accordance with protocol 2024/ETH00128.
